BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stange EF, Wehkamp J. Recent advances in understanding and managing Crohn's disease. F1000Res 2016;5:2896. [PMID: 28163902 DOI: 10.12688/f1000research.9890.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 de Bruyn M, Vermeire S. NOD2 and bacterial recognition as therapeutic targets for Crohn’s disease. Expert Opinion on Therapeutic Targets 2017;21:1123-39. [DOI: 10.1080/14728222.2017.1397627] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
2 Kang WM, Zhu CZ, Yang XX, Yu JC, Ma ZQ, Ye X, Li K, Liu D. Application of the Onodera prognostic nutrition index and neutrophil-to-lymphocyte ratio in risk evaluation of postoperative complications in Crohn's disease. Sci Rep 2017;7:8481. [PMID: 28814767 DOI: 10.1038/s41598-017-09265-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Schoultz I, Keita ÅV. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function. Cells 2019;8:E193. [PMID: 30813280 DOI: 10.3390/cells8020193] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
4 Yang E, Shen J. The roles and functions of Paneth cells in Crohn's disease: A critical review. Cell Prolif 2021;54:e12958. [PMID: 33174662 DOI: 10.1111/cpr.12958] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Kanda Y, Osaki M, Okada F. Chemopreventive Strategies for Inflammation-Related Carcinogenesis: Current Status and Future Direction. Int J Mol Sci. 2017;18:pii: E867. [PMID: 28422073 DOI: 10.3390/ijms18040867] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
6 Elad S, Zadik Y, Caton JG, Epstein JB. Oral mucosal changes associated with primary diseases in other body systems. Periodontol 2000 2019;80:28-48. [DOI: 10.1111/prd.12265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Davidson A, Diamond B. General Features of Autoimmune Disease. The Autoimmune Diseases. Elsevier; 2020. pp. 17-44. [DOI: 10.1016/b978-0-12-812102-3.00003-8] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
9 Chen GL, Xiong DQ, Jiang ZY, Zhang CM, Hu QY. Diagnostic value of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in Crohn's disease. Shijie Huaren Xiaohua Zazhi 2018; 26(2): 93-98 [DOI: 10.11569/wcjd.v26.i2.93] [Reference Citation Analysis]